Confluence Discovery Technologies, a health innovation company based in St. Louis, Missouri, is set to begin an in-patient clinical trial on an investigational new drug application to be used as treatment for hospitalized patients who have COVID-19.
“What this compound does is it blocks these immune proteins called cytokines, which drive a lot of the inflammation that’s seen in a number of diseases, including rheumatoid arthritis,” said Joe Monahan, Confluence’s Executive Vice President of Research and Development. “As it turns out, these cytokines are involved in the acute respiratory distress syndrome in the Covid-19 that progresses a patient to mechanical ventilation that ultimately can lead to death.”
The company expects to begin trials soon. They plan to have the first round of results later this year. The trial will include 36 patients that are currently hospitalized with COVID-19. Read more here.